Clinical significance of hyperbilirubinemia in the CASTLE study by Uy, J et al.
POSTER PRESENTATION Open Access
Clinical significance of hyperbilirubinemia in the
CASTLE study
JU y
1*,WH u
2, V Wirtz
2, T Hosey
1, D Butcher
3, D McGrath
2, A Farajallah
1
From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010
Purpose of the study
While unconjugated hyperbilirubinemia is associated
with the use of ritonavir-boosted atazanavir (ATV/r), the
nature of the hyperbilirubinemia over time and its clini-
cal significance has not been well-characterized in con-
trolled studies. The purpose of this study is to describe
the patterns and clinical significance of hyperbilirubine-
mia in patients treated with ATV/r in the CASTLE study.
Methods
CASTLE was a randomized, 96-week study to assess the
efficacy and safety of ATV/r vs. lopinavir/r, each with
tenofovir/emtricitabine, in treatment-naïve patients. This
analysis included only ATV/r patients. The proportions
of patients with hyperbilirubinemia (grades 3-4 total
bilirubin elevation) were tabulated for each study visit.
The impact of hyperbilirubinemia on symptoms (jaun-
dice or scleral icterus), ASL/ALT elevations, quality of
life (MOS-HIV physical and mental summary scores),
and adherence (MACS adherence questionnaire) were
described.
Summary of results
Although the proportion of patients with hyperbilirubi-
nemia at any time throughout the study was 44%, the
proportion of ATV/r patients with hyperbilirubinemia at
any single visit was between 12.5% and 21.6%. Of
patients with hyperbilirubinemia at any time, 11% had
grades 2-4 treatment-related jaundice or scleral icterus
at any time (0 of patients without hyperbilirubinemia),
and 4% had grades 3-4 AST/ALT elevations at any time
(3% of patients without hyperbilirubinemia). Quality of
life and adherence in patients without and with hyperbi-
lirubinemia. Table 1.
Conclusions
Hyperbilirubinemia, while common in patients on ATV/
r at any time through 96 weeks in the CASTLE study,
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Table 1
Patients without hyperbilirubinemia Patients with hyperbilirubinemia
MOS-HIV Physical Summary Score Categories at Week 96
Improvement 76/138 (55%) 70/128 (55%)
No change 35/138 (25%) 29/128 (23%)
Worsening 27/138 (20%) 29/128 (23%)
MOS-HIV Mental Summary Score Categories at Week 96
Improvement 97/138 (70%) 92/128 (72%)
No change 25/138 (18%) 18/128 (14%)
Worsening 16/138 (12%) 18/128 (14%)
Adherence Through Week 96
To regimen 154/186 (83%) 147/176 (84%)
To ATV 159/186 (85%) 153/176 (87%)
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any medium, provided the original work is properly cited.was less frequent at any single time point and not asso-
ciated with related symptoms in most patients. The pre-
sence of hyperbilirubinemia did not affect AST/ALT
elevations, quality of life, or adherence. These data sug-
gest that hyperbilirubinemia observed with ATV/r does
not impact clinical outcomes.
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